Bowmark Capital related stories
All articles and analysis
Bowmark makes three promotionsThe UK mid market firm has named Julian Masters as senior partner accompanied by two other changes in the firm’s deal team.
- Palamon, Bowmark bolster deal teams
Ali Rahmatollahi joins Palamon from Morgan Stanley, while Bowmark has hired a former Darwin exec
- Bowmark enjoys another lightning fundraise
The UK firm raised £375m in just 10 weeks - mostly from existing LPs.
- OPTrust private equity returns 20.5%
The C$14.7bn pension has plans to grow its private equity allocation from 4.5% to 15% during the next few years.
- Friday Letter: It's getting tougher out there
Non-traditional lenders are the only way to get big deals away, while the mid-market, long held up as evidence of the buyout model’s resilience, is looking trickier too. To make matters worse: vendors are battling with uncertainty.
- OPTrust grows private equity
The $14bn pension system has hired TD Bank's William Hatanaka (pictured) following the departure of CEO Stephen Griggs in April. OPTrust is increasing its private equity allocation from 4% to 15%.
- UK lower mid-market grows
Despite fears that the UK economy is teetering on the brink of recession, the country’s lower mid-market appears to be in good health, according to Lyceum Capital in conjunction with CASS Business School.
- Carlyle and Hellman poised for $3.9bn take-private
The firms’ $3.9bn acquisition of Pharmaceutical Product Development will be one of the largest recent deals in a hot healthcare and pharmaceutical market.
- Baird notches fourth healthcare exit
The firm’s sale of Medical Education Technologies to defense contractor CAE is its fourth exit from the healthcare industry this year.
- Centerbridge makes $300m pharmaceutical bet
The New York firm has invested in Remedi SeniorCare, a Sterling Partners portfolio company, on the heels of closing its latest fund at $4.25bn.